Efficacy of Stromal Vascular Fraction Versus Platelet Rich Plasma in Treatment of Androgenitic Alopecia

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexMale
Age18-60
SponsorKasr El Aini Hospital

About this trial

The goal of this randomized controlled clinical trial is to test the efficacy \& safety of stromal vascular fraction in treatment of AGA \& compare it to PRP The main questions it aims to answer are:

* efficacy \& safety of SVF for treatment of AGA patients * comparing it to PRP in treatment of AGA Participants will receive a single session of SVF in one half of the scalp \& a single session of PRP in the other half.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

18 years or older.

Hamilton score I to VI in male patients.

Disqualifiers

Patients with active infection, malignancy, autoimmune disease, and on current anticoagulant therapy.

Patient on chemotherapy during the last 5 years.

patients on topical or systemic treatment of AGA

Trial design

Design model

Parallel

Treatments tested in this trial

  • stromal vascular fraction or platelet rich plasma

    Procedure/Surgery

    stromal vascular fraction will be injected in one half of the scalp \& PRP will be injected in the other half

Treatment groups

20 Participants
are divided into 2 treatment groups
Group A: stromal vascular fraction sideActive comparator 1 intervention
Group B: PRP sideActive comparator 1 intervention

Trial outcomes

Primary outcomes

1

comparison of SVF versus PRP

to compare the mean difference in hair density,thickness, Norwood Hamilton scale, patient global assessment, patient satisfaction \& physician global assessment scores between SVF \& PRP.

Time frame
at 3 & 6 months after the sessions

Secondary outcomes

1

Detecting efficacy of SVF in treatment of AGA

To detect provment in hair thickness \& diameter

Time frame
at 3 & 6 months

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

This trial is not recruiting at the moment. You can still explore other options: